Matthew Herper from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: The end of 23andMe’s drug discovery dream - 6 days ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago STAT+: How will Trump’s election change the FDA? History yields some clues - 11 days ago STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion - 2 months ago STAT+: Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback - 3 months ago STAT+: 23andMe board rejects co-founder Anne Wojcicki’s offer to take company private - 4 months ago STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 4 months ago STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 5 months ago New data show the HPV vaccine prevents cancer in men, too. Why don’t more people get it? - 6 months ago STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more - 6 months ago STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study - 7 months ago STAT+: WHO scientists question Grail’s plan for evaluating its multi-cancer Galleri blood test - 7 months ago STAT+: Roivant CEO: New deals could ‘materialize later this year’ - 8 months ago A study says intermittent fasting is making people drop dead. Oh, come on - 8 months ago STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone - 8 months ago STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest - 9 months ago STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act - 9 months ago STAT+: Pfizer is about to make a big push in cancer. Will investors listen? - 9 months ago STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira - 9 months ago STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing? - 10 months ago The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago STAT+: Nvidia says a biological revolution is happening now. But is it? - 10 months ago This is the TLDR of JPM Day 1 - 10 months ago STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves - 10 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 11 months ago STAT+: Amy Abernethy to step down as Verily’s chief medical officer in latest departure from company - 11 months ago STAT+: Pfizer says 2024 profits will fall far below expectations - 11 months ago STAT+: Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it? - 12 months ago STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research - 12 months ago STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - 12 months ago STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment - 12 months ago Key questions (and answers) about the historic approval of a CRISPR-based medicine - about 1 year ago Study suggests Covid rebound is far more common with Paxlovid than without - about 1 year ago STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug - about 1 year ago STAT+: After decades in use, heart stents finally beat placebo. It took a bold researcher - about 1 year ago In experiment, electrical stimulation of the spinal cord helps a patient with Parkinson’s to walk - about 1 year ago STAT+: Eli Lilly to pay $200 million for Beam’s share of drugs from gene-editing firm Verve - about 1 year ago STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio - about 1 year ago STAT+: Why Sanofi got shellacked - about 1 year ago STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits - about 1 year ago STAT+: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies - about 1 year ago STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion - about 1 year ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
3	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion - 2 months ago STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - 12 months ago
4	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 11 days ago The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago This is the TLDR of JPM Day 1 - 10 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 11 months ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 4 months ago
7	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study - 7 months ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago This is the TLDR of JPM Day 1 - 10 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 11 months ago
9	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	The highs — and lows — of JPM 2024 you should pay attention to - 10 months ago This is the TLDR of JPM Day 1 - 10 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 11 months ago Key questions (and answers) about the historic approval of a CRISPR-based medicine - about 1 year ago
10	Mohana Ravindranath STAT News Health tech reporter at STAT. Oakland, CA + Washington, D.C. Health techreporting	STAT+: Burning questions for the 2024 JPM Healthcare Conference - 11 months ago